Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PDE9A | O76083 | 2/20 | 0.31 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.31 |
| ▸ | PDE1A | P54750 | 1/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.30 |
| ▸ | BPTF | Q12830 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20444036 | 0.78 | KMT2A (0.34) | KDM4EKMT2AHTR3AALDH1A1PDE9A | |
| SCHEMBL17249520 | 0.78 | PTGS1 (0.36) | KDM4EKMT2AHTR3AIDH1ALDH1A1 | |
| SCHEMBL25975005 | 0.76 | HTR3A (0.36) | KDM4EKMT2AHTR3ATOP2APDE1C | |
| SCHEMBL11287052 | 0.76 | KDM4E (0.33) | KDM4EKMT2AHTR3AALDH1A1PDE9A | |
| SCHEMBL16663602 | 0.68 | KDM4E (0.34) | KDM4EKMT2APDE1CPDE1APDE1B | |
| SCHEMBL15077058 | 0.68 | ADORA3 (0.41) | KDM4EKMT2APDE9APDE1C | |
| SCHEMBL27300510 | 0.67 | PDE1C (0.39) | KDM4EALDH1A1PDE9APDE1CPDE1A | |
| SCHEMBL18237332 | 0.67 | TOP2A (0.33) | ALDH1A1TOP2A | |
| SCHEMBL20443987 | 0.66 | PTGS1 (0.49) | KDM4EIDH1ALDH1A1 | |
| SCHEMBL21077362 | 0.66 | PDE1A (0.37) | KDM4EKMT2APDE1CPDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10676477-B2 | Factor XIa macrocycle inhibitors bearing a non-aromatic P2' group | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-09 | — | — | US | disclosed |
| US-20180222889-A1 | NOVEL SUBSTITUTED GLYCINE DERIVED FXIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180222889-A1 | NOVEL SUBSTITUTED GLYCINE DERIVED FXIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180215755-A1 | FACTOR XIA MACROCYCLIC INHIBITORS BEARING ALKYL OR CYCLOALKYL P2' MOIETIES | BRISTOL MYERS SQUIBB CO (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180141932-A1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141932-A1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141932-A1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | KDM4E 603/4885KMT2A 1075/4885HTR3A 2919/4885 |
| US-20180215755-A1 | FACTOR XIA MACROCYCLIC INHIBITORS BEARING ALKYL OR CYCLOALKYL P2' MOIETIES | TFPI, TFPI2, F11 | KDM4E 1090/4885KMT2A 1270/4885HTR3A 1553/4885 |
| US-10676477-B2 | Factor XIa macrocycle inhibitors bearing a non-aromatic P2' group | TFPI, TFPI2, F2 | KDM4E 998/4885KMT2A 2042/4885HTR3A 1346/4885 |
| US-20180222889-A1 | NOVEL SUBSTITUTED GLYCINE DERIVED FXIA INHIBITORS | TFPI, TFPI2, F2 | KDM4E 1793/4885KMT2A 1073/4885HTR3A 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.